{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:19:33Z","timestamp":1787653173227,"version":"build-2736575974"},"reference-count":26,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chemotherapy and monoclonal antibodies are increasingly associated with hypersensitivity reactions (HSRs), including anaphylaxis. Desensitization modulates allergic responses to drugs, facilitating temporary tolerance to full therapeutic doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Observational, descriptive, ambispective study from August 2020 to August 2024, including cancer patients who came for treatment administration and developed a hypersensitivity reaction, and underwent 3-bag 12-step desensitization in 5.67\u2005h. Demographic variables, atopic and oncological history, hypersensitivity reactions, breakthrough reactions (BTR) during desensitization, and safety of the protocols were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>927 desensitization in 219 patients, 20.7% with personal atopy and 84% female. The most common oncological diagnoses were: breast cancer (23.3%), ovarian (22.1%), and cervical (15.9%). The drugs of the most hypersensitivity reactions were Paclitaxel 372 (40.2%), Carboplatin 172 (18.7%), Oxaliplatin 66 (7.1%), Docetaxel 59 (6.4%), Rituximab 40 (4.3%) and Trastuzumab 40 (4.3%). The most frequent hypersensitivity reactions were cutaneous 172 (18.6%), respiratory 173 (18.7%) and cardiovascular 165 (17.8%) with a severity scale of Brown I 12.1%, Brown II 43.3% and Brown III 44.6%. During desensitization 80\/927 cases (8.6%) had breakthrough reactions: cutaneous 56 (6%), respiratory 18 (1.9%) and cardiovascular 17 (1.8%), of which the majority were mild reactions. All patients completed their desensitization with no deaths reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study reports that patients undergoing desensitization protocols had a lower percentage of breakthrough reactions compared to the previous hypersensitivity reactions, showing that this procedure is safe and effective to continue first-line oncological treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251328346","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T08:21:41Z","timestamp":1753690901000},"page":"1016-1023","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypersensitivity reactions to chemotherapy and biologics: Outcomes and safety of 927 desensitization in Mexico"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-6934","authenticated-orcid":false,"given":"Rosalaura","family":"Villarreal-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4977-0618","authenticated-orcid":false,"given":"Leslie Astrid","family":"De la Fuente","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cadenas-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6908-0171","authenticated-orcid":false,"given":"Itzayana","family":"Ortega-Franco","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianela","family":"Madrazo-Morales","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathia","family":"S\u00e1enz-Cant\u00fa","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryl","family":"Cadena-Rosales","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Pi\u00f1eiro Retif","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3723-8525","authenticated-orcid":false,"given":"Oscar","family":"Vidal-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411257"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01472"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.15113"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043886"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.04.029"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003466"},{"key":"e_1_3_3_8_2","article-title":"Hypersensitivity reactions to platinum agents and taxanes","author":"Tsao LR","year":"2016","unstructured":"Tsao LR, Young FD, Otani IM, et al. Hypersensitivity reactions to platinum agents and taxanes. Clin Rev Allergy Immunol 2016. doi:https:\/\/doi.org\/10.1007\/s12016-021-08877-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.018"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.12.001"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061316"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.12.006"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.07.031"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.02.044"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2022.786822"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2024.1460326"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2024.16.2.142"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.10.039"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.202"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100619"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14984"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.12.019"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S419722"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1586\/eci.11.75"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000454808"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.05.007"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-014-8416-0"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251328346","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251328346","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251328346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:31:36Z","timestamp":1787650296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251328346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10781552251328346"],"URL":"https:\/\/doi.org\/10.1177\/10781552251328346","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}